SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH 3 YEARS: LONG-TERM RESULTS OF TWO RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDIES

被引：0
|
作者：
Kvien, T. K. [1 ]
Deodhar, A. [2 ]
Gossec, L. [3 ]
Conaghan, P. G. [4 ]
Strand, V. [5 ]
Ostergaard, M. [6 ]
Williams, N. [7 ]
Porter, B. [8 ]
Gandhi, K. [8 ]
Jugl, S. [9 ]
机构：
[1] Diakonhjemmet Hosp, Oslo, Norway
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] UPMC Univ Paris 06, Paris, France
[4] Univ Leeds, Leeds, W Yorkshire, England
[5] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[6] Copenhagen Ctr Arthrit Res COPECARE, Glostrup, Denmark
[7] RTI Hlth Solut, Durham, NC USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
363
引用
收藏
页码：S9 / S9
页数：1
相关论文
共 50 条
  • [1] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH 3 YEARS: LONG-TERM RESULTS OF TWO RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDIES
    Kvien, T. K.
    Deodhar, A.
    Gossec, L.
    Conaghan, P. G.
    Strand, V.
    Ostergaard, M.
    Williams, N.
    Porter, B.
    Gandhi, K.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 355 - 356
  • [2] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH THREE YEARS: LONG-TERM RESULTS OF TWO RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE III STUDIES
    Marzo-Ortega, Helena
    Kvien, Tore K.
    Deodhar, Atul A.
    Gossec, Laure
    Conaghan, Philip G.
    Strand, Vibeke
    Ostergaard, Mikkel
    Williams, Nicole
    Porter, Brian
    Gandi, Kunal
    Jugl, Steffen
    RHEUMATOLOGY, 2018, 57
  • [3] Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials
    Kvien, Tore K.
    Conaghan, Philip G.
    Gossec, Laure
    Strand, Vibeke
    Ostergaard, Mikkel
    Poddubnyy, Denis
    Williams, Nicole
    Porter, Brian
    Shete, Abhijit
    Gilloteau, Isabelle
    Deodhar, Atul
    ARTHRITIS CARE & RESEARCH, 2022, 74 (05) : 759 - 767
  • [4] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Efficacy and Safety Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
    Baeten, Dominique
    Braun, Jurgen
    Sieper, Joachim
    Dougados, Maxime
    Deodhar, Atul A.
    Baraliakos, Xenofon
    Porter, Brian
    Gong, Yankun
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [5] Reduction in fatigue in patients with active ankylosing spondylitis: results of two phase 3 studies of secukinumab
    Kvien, T. K.
    Conaghan, P.
    Deodhar, A.
    Gossec, L.
    Ostergaard, M.
    Canete, J.
    Gandhi, K.
    Richards, H.
    Williams, N.
    Jugl, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 35 - 36
  • [6] REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS OF TWO PHASE 3 STUDIES OF SECUKINUMAB
    Kvien, T. K.
    Conaghan, P. G.
    Deodhar, A.
    Gossec, L.
    Ostergaard, M.
    Canete, J.
    Gandhi, K.
    Richards, H.
    Williams, N.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 823 - 823
  • [7] REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS ARE SUSTAINED OVER 2 YEARS: LONG-TERM RESULTS OF TWO PHASE 3 STUDIES WITH SECUKINUMAB
    Gossec, L.
    Kvien, T. K.
    Conaghan, P. G.
    Ostergaard, M.
    Canete, J.
    Gaillez, C.
    Mpofu, S.
    Davenport, E.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 351 - 351
  • [8] Reduction in fatigue in patients with active psoriatic arthritis is sustained over 2 years: long-term results of two phase 3 studies of secukinumab
    Kvien, T. K.
    Gossec, L.
    Conaghan, P.
    Ostergaard, M.
    Canete, J.
    Gaillez, C.
    Mpofu, S.
    Davenport, E.
    Jugl, S.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 33 - 33
  • [9] Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Inman, Robert D.
    Davis, John C., Jr.
    van der Heijde, Desiree
    Dickman, Laura
    Sieper, Joachim
    Kim, Sung Il
    Mack, Michael
    Han, John
    Visvanathan, Sudha
    Xu, Zhenhua
    Su, Benjamin
    Beutler, Anna
    Braun, Juergen
    ARTHRITIS AND RHEUMATISM, 2008, 58 (11): : 3402 - 3412
  • [10] Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
    Mease, Philip J.
    McInnes, Iain B.
    Kirkham, Bruce
    Kavanaugh, Arthur
    Rahman, Proton
    van der Heijde, Desiree
    Landewe, Robert B. M.
    Nash, P.
    Pricop, Luminita
    Wang, Zailong
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345